Related Experiment Videos
HS-599: a novel long acting opioid analgesic does not induce place-preference in rats
R Lattanzi1, L Negri, E Giannini
1Department of Human Physiology and Pharmacology, University 'La Sapienza', P.le Aldo Moro, 5, I-00185 Rome, Italy.
British Journal of Pharmacology
|September 21, 2001
Summary
HS-599, a novel buprenorphine derivative, offers potent, long-lasting pain relief in rats by acting as a mu-opioid receptor agonist. Unlike traditional opioids, it does not induce addictive behaviors, making it a promising analgesic candidate.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- Buprenorphine is a widely used opioid analgesic with a complex pharmacological profile.
- Novel derivatives are sought to improve efficacy and reduce side effects, such as addiction potential.
Purpose of the Study:
- To characterize the pharmacological properties of HS-599, a new didehydrobuprenorphine derivative.
- To evaluate its antinociceptive effects, receptor binding affinity, and potential for conditioned place preference.
Main Methods:
- Subcutaneous administration of HS-599 in rats for antinociception tests (tail-flick and plantar).
- Radioligand binding assays to determine opioid receptor affinity.
- In vitro studies using isolated guinea-pig and mouse/rabbit vas deferens preparations to assess opioid receptor interactions.
Main Results:
- HS-599 demonstrated potent and long-lasting antinociception, exceeding buprenorphine's efficacy.
- It exhibited higher affinity and selectivity for mu-opioid receptors compared to buprenorphine.
- HS-599 did not induce conditioned place preference in rats, unlike buprenorphine and morphine.
Conclusions:
- HS-599 is a novel buprenorphine derivative with superior mu-opioid receptor affinity, selectivity, and potency.
- It produces intense, long-lasting antinociception without the addictive potential observed with other opioids.
- HS-599 represents a promising candidate for developing new analgesics with an improved safety profile.